Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience

Apremilast, a phosphodiesterase-4 inhibitor, has shown promise to have a potential beneficial metabolic effect. We conducted a single-centre retrospective study on adult patients with moderate-to-severe psoriasis who underwent apremilast treatment over at least 12 and 52 weeks, respectively. Baselin...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2024-03, Vol.14 (3), p.395
Main Authors: Guerra, Prisca, Di Cesare, Antonella, Rosi, Elia, Scandagli, Ilaria, Silvi, Gianmarco, Nunziati, Giulia, Prignano, Francesca
Format: Article
Language:English
Subjects:
apremilast
Body mass index
Body size
Care and treatment
Cholesterol
comorbidities
Comorbidity
Density
Dermatologic agents
Dermatology
Dextrose
Diagnosis
Disease
Fatty acids
Formulae, receipts, prescriptions
Glucose
Health aspects
High density lipoprotein
Hypertension
lipid profile
Lipids
Low density lipoprotein
Low density lipoproteins
Medical research
Medicine, Experimental
metabolic effect
Metabolism
Outpatient care facilities
Overweight
Patients
Psoriasis
Psoriatic arthritis
Reduction
Roflumilast
Skin diseases
Subgroups
Triglycerides
Type 2 diabetes
Weight
Weight control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Apremilast, a phosphodiesterase-4 inhibitor, has shown promise to have a potential beneficial metabolic effect. We conducted a single-centre retrospective study on adult patients with moderate-to-severe psoriasis who underwent apremilast treatment over at least 12 and 52 weeks, respectively. Baseline characteristics, weight, lipid profile, and fasting glucose levels were collected at baseline and at 12, 24, and 52 weeks. Furthermore, we conducted a narrative review of the current scientific knowledge on the metabolic effects of apremilast in patients with psoriasis and psoriatic arthritis. We observed a significant reduction in average weight and body mass index (BMI) in patients treated with apremilast in both the initial and the subgroup analysis, a significant reduction in triglycerides levels at 24 and 52 weeks, and a significant increase in high-density lipoprotein (HDL) levels at 52 weeks, whereas there were no significant changes in total cholesterol or low-density lipoprotein (LDL) concentrations over the 52-week treatment period. These findings suggest a potential positive impact of apremilast on both weight management and lipid profile in individuals with moderate-to-severe psoriasis in the medium-long term.
ISSN:2075-1729
2075-1729
DOI:10.3390/life14030395